This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock AQXP vs. IRON, BHC, ARQT, BHVN, SDGR, EWTX, JANX, ETNB, DYN, and SPRYShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Disc Medicine (IRON), Bausch Health Companies (BHC), Arcutis Biotherapeutics (ARQT), Biohaven (BHVN), Schrödinger (SDGR), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), 89bio (ETNB), Dyne Therapeutics (DYN), and ARS Pharmaceuticals (SPRY). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Disc Medicine Bausch Health Companies Arcutis Biotherapeutics Biohaven Schrödinger Edgewise Therapeutics Janux Therapeutics 89bio Dyne Therapeutics ARS Pharmaceuticals Disc Medicine (NASDAQ:IRON) and Aquinox Pharmaceuticals (NASDAQ:AQXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, community ranking, media sentiment, profitability, risk, institutional ownership and analyst recommendations. Which has more volatility & risk, IRON or AQXP? Disc Medicine has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Aquinox Pharmaceuticals has a beta of -7.37, indicating that its stock price is 837% less volatile than the S&P 500. Which has stronger valuation & earnings, IRON or AQXP? Aquinox Pharmaceuticals has higher revenue and earnings than Disc Medicine. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.92-12.76Aquinox Pharmaceuticals$25M20.56-$31.58MN/AN/A Does the media prefer IRON or AQXP? In the previous week, Disc Medicine had 6 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 6 mentions for Disc Medicine and 0 mentions for Aquinox Pharmaceuticals. Disc Medicine's average media sentiment score of 1.42 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Overall Sentiment Disc Medicine Positive Aquinox Pharmaceuticals Neutral Do analysts prefer IRON or AQXP? Disc Medicine currently has a consensus target price of $98.80, indicating a potential upside of 97.52%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts plainly believe Disc Medicine is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders & institutionals have more ownership in IRON or AQXP? 83.7% of Disc Medicine shares are held by institutional investors. Comparatively, 71.7% of Aquinox Pharmaceuticals shares are held by institutional investors. 4.2% of Disc Medicine shares are held by insiders. Comparatively, 4.0% of Aquinox Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor IRON or AQXP? Aquinox Pharmaceuticals received 240 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 85.51% of users gave Disc Medicine an outperform vote while only 71.88% of users gave Aquinox Pharmaceuticals an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5985.51% Underperform Votes1014.49%Aquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% Is IRON or AQXP more profitable? Disc Medicine's return on equity of -25.24% beat Aquinox Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% Aquinox Pharmaceuticals N/A -30.13%-28.08% SummaryDisc Medicine beats Aquinox Pharmaceuticals on 12 of the 15 factors compared between the two stocks. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$513.88M$6.72B$5.52B$8.58BDividend YieldN/A2.49%5.27%4.18%P/E RatioN/A8.7027.3020.13Price / Sales20.56249.96414.54162.07Price / CashN/A65.8538.2534.64Price / Book7.066.586.984.69Net Income-$31.58M$143.49M$3.23B$248.08M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$21.83-4.8%N/A-42.4%$513.88M$25M0.008IRONDisc Medicine1.9217 of 5 stars$47.73+2.2%$98.80+107.0%+27.9%$1.65BN/A-11.9930Positive NewsBHCBausch Health Companies4.6605 of 5 stars$4.49-1.0%$7.42+65.4%-24.2%$1.64B$9.73B-37.3719,900Positive NewsShort Interest ↓ARQTArcutis Biotherapeutics2.2066 of 5 stars$13.48+3.4%$18.80+39.5%+98.5%$1.61B$212.82M-7.53150News CoveragePositive NewsGap UpBHVNBiohaven2.7732 of 5 stars$15.62+5.4%$59.46+280.8%-49.5%$1.59BN/A-1.67239Gap UpHigh Trading VolumeSDGRSchrödinger2.4104 of 5 stars$21.69+0.3%$32.80+51.2%+13.2%$1.59B$230.49M-9.27790EWTXEdgewise Therapeutics3.2418 of 5 stars$14.69+2.9%$40.22+173.8%-13.7%$1.55BN/A-9.7960Positive NewsAnalyst ForecastJANXJanux Therapeutics1.5993 of 5 stars$25.01+5.1%$95.25+280.8%-40.6%$1.48B$9.34M-21.3830Positive NewsShort Interest ↑ETNB89bio2.6074 of 5 stars$10.11+2.7%$26.43+161.4%+26.5%$1.48BN/A-3.4740DYNDyne Therapeutics2.9076 of 5 stars$12.70+6.2%$45.54+258.6%-52.5%$1.44BN/A-3.57100SPRYARS Pharmaceuticals2.6743 of 5 stars$14.46+0.2%$31.00+114.4%+64.5%$1.42B$97.12M-28.3590Positive News Related Companies and Tools Related Companies IRON Competitors BHC Competitors ARQT Competitors BHVN Competitors SDGR Competitors EWTX Competitors JANX Competitors ETNB Competitors DYN Competitors SPRY Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AQXP) was last updated on 6/9/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredThe “black glass” breakthrough behind AI’s next leapAI is advancing fast… But there’s one problem almost no one’s talking about. Power.True Market Insiders | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AQXP Stock Free AQXP Stock Alerts